

Applicant: Erik Buntinx  
Serial No.: 10/752,423  
Filed: January 6, 2004  
page 2 of 14

Amendments to the Claims:

Please cancel claims 2, 3, 4, 6, 8, 11-15 and 17-63 without prejudice or disclaimer, and amend claims 1, 7, 9 and 10 as set forth below.

1. (Currently amended) A method for treating ~~an anxiety disease or disorder with an underlying dysregulation of emotional functionality~~ comprising administering to a patient pipamperone ~~a compound having (i) a selective affinity for the Dopamine 4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, wherein said compound is administered to said patient in a dose ranging between 5 and 15 mg of the active ingredient, wherein a selective serotonin re-uptake inhibitor (SSRI) is administered to the patient simultaneously with, separate from or sequential to the administration of pipamperone to augment the therapeutic effect of said SSRI or to provide a faster onset of the therapeutic effect of said SSRI.~~

2-6. (Canceled)

7. (Currently amended) The method of claim 1, ~~4~~, wherein pipamperone ~~the first compound~~ is administered daily at least one day before administering said SSRI ~~second compound~~.

8. (Canceled)

9. (Currently amended) The method of claim 1, ~~8~~, wherein said selective serotonin re-uptake inhibitor is chosen from the group consisting of CITALOPRAM,

Applicant: Erik Buntinx  
Serial No.: 10/752,423  
Filed: January 6, 2004  
page 3 of 14

fluoxetine, venlafaxine, fluvoxamine, paroxetine, sertraline, milnacipran and duloxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

10. (Currently amended) The method of claim 1, 9 wherein said serotonin re-uptake inhibitor is CITALOPRAM and is administered in a dose ranging between 10 and 40 mg of the active ingredient.

11-63. (Canceled)